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The influence of qnrA1 on the development of quinolone resistance in Enterobacteriaceae was evaluated by
using the mutant prevention concentration parameter. The expression of qnrA1 considerably increased the
mutant prevention concentration compared to strains without this gene. In the presence of qnrA1, mutations
in gyrA and parC genes were easily selected to produce high levels of quinolone resistance.
Fluoroquinolone resistance in Enterobacteriaceae is usually
the result of mutations in chromosomal genes for type II topo-
isomerases or in genes coding for or regulating efflux pumps
and/or porins (6). Recent reports indicate that quinolone re-
sistance may also be plasmid mediated by the qnrA, qnrS, qnrB,
or aac(6)-Ib-cr genes (12, 16). Although qnrA (and, presum-
ably, related) genes confer low-level resistance on their own,
when found in the presence of other mechanisms, they are able
to help select for mutants with increased levels of fluoroquin-
olone resistance (6, 11, 16).
A major goal of antimicrobial therapy is to achieve sufficient
drug exposure in relation to MIC for optimal efficacy at the site
of infection. Activity can be assessed by using the mutant
prevention concentration (MPC). This is the drug concentra-
tion that prevents the growth of the least-susceptible single-
step mutant present in a large bacterial population, taking into
account resistant mutant subpopulations present prior to an-
timicrobial treatment (1, 5). The mutant selection window, the
antibiotic concentration found between MIC and MPC, is
where single-step mutants can be enriched (5).
The aim of the present study was to determine the influence
of qnrA1 on the development of quinolone resistance in En-
terobacteriaceae using the MPC parameter. For this purpose,
14 strains were evaluated. These included: (i) four Klebsiella
pneumoniae clinical strains containing qnrA1 with different lev-
els of fluoroquinolone susceptibility (Tables 1 and 2) (11, 17)
and (ii) three groups of isogenic strains that both express and
do not express qnrA1 (Table 1). The primers used to clone
qnrA1 in pACYC184 (New England Biolabs, Inc., Barcelona,
Spain) were 5-CGGCAGTTAAAATTGGGGCT-3 and 5-G
ACCAGACTGCATAAGCAACAC-3.
qnrA1 expression as the only quinolone resistance mecha-
nism did not bring about fluoroquinolone resistance; however,
the association of qnrA1 with other mechanisms, such as porin
loss and Ser83Phe substitution in the GyrA protein of the K.
pneumoniae C2 pMG252 strain, did produce a phenotype of
intermediate fluoroquinolone susceptibility, which supported
the additive nature of the mechanism (Table 2) (10). This
could imply an important tool in the acquisition of high quin-
olone resistance levels in relation to plasmid-mediated quino-
lone resistance (14, 17, 21).
MPC assays were performed on all 14 strains, as previously
described (9), permitting colony growth for up to 96 h. Most
strains required between 48 and 96 h of incubation before
resistant colonies were observable, except in the N5 and 1960
strains for moxifloxacin and in the C2 and C2/pMG252 strains
for ciprofloxacin and moxifloxacin (Table 2). The MPC values
of each fluoroquinolone for the different strains expressing the
qnrA1 gene as the only known quinolone resistance mechanism
(Escherichia coli DH10BqnrA1; E. coli J53 transconjugants
containing qnrA1) reached levels (2 to 4 g/ml) approaching
the peak serum concentrations attained during therapy (Table
2) (5, 7, 20). MPC values for the non-qnrA1-producing isogenic
controls ranged from 0.015 to 0.125 g/ml (Table 2). These
values were much higher in strains containing additional resis-
tance mechanisms. The MPCs of clinical qnrA1-containing K.
pneumoniae strains ranged from 4 to 64 g/ml for the various
fluoroquinolones. MPC values for K. pneumoniae C2 and K.
pneumoniae C2 pMG252 strains were 4 to 8 g/ml and 32 to
128 g/ml, respectively, showing, once again, the effect of the
qnrA1 gene on the MPC parameter. A potential consequence
of a suboptimal therapy selecting for resistance can be exem-
plified by considering the case of mutants selected one dilution
step below the MPC whose MIC is equal to or greater than its
MPC value (Table 2).
Plasmid-mediated quinolone resistance enables mutant bac-
teria with low levels of resistance to survive long enough for
them to grow and emerge during fluoroquinolone treatment.
Interestingly, the MICs of some mutants from transconjugants
containing qnrA1 and deriving from E. coli J53 and K. pneu-
moniae C2/pMG252 were as high as 4 g/ml and 32 to 128
g/ml, respectively (Table 2). Primers used to detect mutations
in gyrA, parC, and qnrA1 have been described previously (8,
19). Mutations in the quinolone resistance-determining re-
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gions of gyrA or parC, which are related to the fluoroquinolone
resistance in Enterobacteriaceae, were found in qnrA1-express-
ing mutants (Ser83Phe and Asp87Tyr in GyrA, and Ser80Ile
and Val87Asp in ParC). No mutations were found either in the
qnrA1 coding sequences or in their promoter sequences (data
not shown) (18). Additional mutations in qnrA1-containing
strains relating to quinolone resistance and detected in the
type II topoisomerase genes are a reflection of the ability of
this mechanism to select for mutants with additional chromo-
somal quinolone resistance mechanisms. Such mechanisms,
because of their additive nature, lead to therapeutic failure
(10). In vivo selection of fluoroquinolone-resistant E. coli ex-
pressing the qnrA1 gene was reported recently in the case of a
patient with a urinary tract infection being treated with nor-
floxacin for an infection due to a ciprofloxacin-susceptible iso-
late (13). These data indicate the role of qnrA1 in the selection
and generation of quinolone-resistant mutants.
On the other hand, qnrA1 greatly eased the mutant selection
(Fig. 1). For example, in the presence of qnrA1 (E. coli
DH10BqnrA1) and at 0.25 g/ml, more than 103 resistant
colonies grew from an initial population of 1010 bacteria, and
colonies could still be recovered at ciprofloxacin concentra-
tions of 1 to 2 g/ml (Fig. 1A). Expression of qnrA1 from a
natural plasmid in E. coli J53 produced over 105 resistant
colonies grown at 1 g/ml for J53 pMG252, and colonies could
still be recovered at moxifloxacin concentrations of 2 to 4
g/ml (Fig. 1B). In the case of isogenic strains of K. pneu-
moniae C2, the expression of qnrA1 from a natural plasmid
TABLE 1. Quinolone susceptibility characteristics of strains included in this study
Strain Description CIPsusceptibilitya
Mechanisms associated with quinolone
resistance Source or
reference
qnrA1b GyrA ParC Porinsd
UAB1 K. pneumoniae clinical strain I  wtc wt  11
N5 K. pneumoniae clinical strain S  wt wt  17
1960 K. pneumoniae clinical strain S  Ser83Phe wt  17
1132 K. pneumoniae clinical strain R  wt wt  17
DH10B E. coli reference lab strain S – wt wt 
DH10B/pACYC184 E. coli DH10B containing pACYC184 vector S – wt wt  This study
DH10BqnrA1 E. coli DH10B containing qnrA1 cloned in
pACYC184 vector
S  wt wt  This study
E. coli J53 E. coli reference lab strain S – wt wt 
J53/pMG252 E. coli J53 transconjugant derived from UAB1 S  wt wt  11
J53/pN5 E. coli J53 transconjugant derived from N5 S  wt wt  17
J53/p1960 E. coli J53 transconjugant derived from 1960 S  wt wt  17
J53/p1132 E. coli J53 transconjugant derived from 1132 S – wt wt  17
C2 K. pneumoniae clinical strain S – Ser83Phe wt – 11
C2/pMG252 C2 transconjugant derived from UAB1 I  Ser83Phe wt – This study
a S, susceptible, I, intermediate susceptibility, R, resistance according to CLSI guidelines (4).
b , Presence and expression of qnrA1; , no expression.
c wt, wild type.
d  or  indicates the presence or absence of porins, respectively.
TABLE 2. Fluoroquinolone MPCs and MICs for clinical and isogenic strains used in this study and derived resistant mutantsa
Strain
MIC MPC MPC/MIC (MSW) MIC for mutantsb MPC time (h)windowc
CIP LFX MXF CIP LFX MXF CIP LFX MXF CIP LFX MXF CIP LFX MXF
UAB1 2 2 4 16 16 32 8 8 8 16–64 16–32 32–64 72–96 96 72
N5 0.25 0.5 0.5 4 4 16 16 8 32 8 8 4–8 48 48 24–48
1960 1 2 2 64 64 32 64 32 16 32–64 64 16 72 72 24–48
1132 4 4 8 32 32 32 8 8 4 16 16 16 48 48 72
E. coli DH10B 0.002 0.004 0.002 0.015 0.015 0.06 7.5 3.8 30 0.008 0.008 0.06 72 72 96
E. coli DH10B/pACYC184 0.002 0.004 0.002 0.015 0.015 0.06 7.5 3.8 30 0.008 0.008 0.06 72 72 72
E. coli DH10BqnrA 0.125 0.125 0.125 2 2 2 16 16 16 1 1 0.5 72–96 96 96
E. coli J53 0.004 0.008 0.015 0.06 0.06 0.125 15 7.5 16.7 0.03 0.03 0.5 48 48 72
J53/pMG252 0.25 0.25 0.5 4 4 4 16 16 8 4 2 2–4 96 96 72
J53/pN5 0.125 0.125 0.125 4 4 4 32 32 32 2 4 2 72 96 72
J53/p1960 0.125 0.125 0.125 4 4 4 32 32 32 1 2 4 72 96 72
J53/p1132 0.004 0.008 0.015 0.06 0.06 0.25 15 7.5 16.7 0.03 0.06 0.25 72 48 72
C2 0.25 0.25 0.125 8 8 4 32 32 32 4–8 8 2–8 24–48 48 24–48
C2/pMG252 2 2 1 128 128 32 64 64 32 64–128 64 32–64 24–48 72 24–48
a MICs (in g/ml) were determined by microdilution for ciprofloxacin (CIP), levofloxacin (LFX), or moxifloxacin (MXF). MPC values (in g/ml) were determined
for ciprofloxacin, levofloxacin, or moxifloxacin on Mueller-Hinton plates as the lowest antibiotic concentration (in the range of concentration steps analyzed) at which
resistant colonies do not form. The MSW is the mutant selection window, the antibiotic concentration found between the MIC and the MPC.
b MIC for CIP (microdilution) for ciprofloxacin- or moxifloxacin-resistant colonies were recovered on Mueller-Hinton plates one step below the MPC value.
c Earliest time (in hours) at which resistant colonies were visible one step below the MPC.
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produced more than 103 resistant colonies grown at 16 g/ml,
and colonies were still visualized at ciprofloxacin concentra-
tions of 64 to 128 g/ml (Fig. 1C), levels higher than peak
serum concentrations attained during drug therapy. In cases of
strains containing qnrA1, doses exceeding MPC in mono-
therapy would not be advisable with approved dosing proce-
dures and evaluations of drug toxicity (2, 3). The increased
frequency of quinolone-resistant mutants in strains which ex-
FIG. 1. MPC assays. MIC and MPC values are indicated on figures by arrows. CIP, ciprofloxacin; MXF, moxifloxacin.
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press qnrA1 at different concentrations below the MPC pro-
vides support for the role of low-level resistance mediated by
the mechanism in selecting for quinolone resistance (11, 15),
particularly if we take into account the MICs observed in
mutants selected below the MPC and include some mutants
obtained from strains whose only quinolone resistance mech-
anism was qnrA1 (Table 2).
Bacteria surviving at MPC were counted after 96 h, as de-
scribed elsewhere (9). The MIC and MPC of these organisms
(isolated at very low frequencies [data not shown]) were similar
to those of the original strains. Although some bacteria sur-
vived MPC for a prolonged period, no quinolone-resistant
mutants were selected, showing that the MPC parameter was
working as specified. It is possible that survival is related to
mutations in the hip genes (high persistence), being enhanced
in the presence of -lactams or fluoroquinolones, and produc-
ing a persistent phenotype at high antimicrobial concentrations
(22).
Mechanisms, such as qnr or the recently described aac(6)-
Ib-cr gene, which are implicated in low-level fluoroquinolone
resistance to plasmid-mediated determinants, may play a sig-
nificant role in the generation of resistant mutants and thera-
peutic failure. This may be because, first, many clinical strains
reported as containing genes that code for plasmid-mediated
fluoroquinolone resistance are susceptible and, second, the
presence of such genes in conjugative plasmid or other mobile
elements may facilitate rapid dissemination in Enterobacteria-
ceae and other bacteria of clinical significance. Animal models
will be necessary in future to perform in vivo validation of
these in vitro data obtained by using the MPC parameter.
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